Published in J Med Genet on March 29, 2006
Pseudoxanthoma elasticum: molecular genetics and putative pathomechanisms. J Invest Dermatol (2009) 2.43
In silico functional profiling of human disease-associated and polymorphic amino acid substitutions. Hum Mutat (2010) 1.81
Elevated dietary magnesium prevents connective tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6(-/-)). J Invest Dermatol (2009) 1.42
Ectopic mineralization of connective tissue in Abcc6-/- mice: effects of dietary modifications and a phosphate binder--a preliminary study. Exp Dermatol (2007) 1.39
Mutations in fam20b and xylt1 reveal that cartilage matrix controls timing of endochondral ossification by inhibiting chondrocyte maturation. PLoS Genet (2011) 1.30
The mineralization phenotype in Abcc6 ( -/- ) mice is affected by Ggcx gene deficiency and genetic background--a model for pseudoxanthoma elasticum. J Mol Med (Berl) (2009) 1.26
Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6(-/-) mice-potential for treatment of pseudoxanthoma elasticum. Clin Transl Sci (2009) 1.19
A single-nucleotide polymorphism in the Abcc6 gene associates with connective tissue mineralization in mice similar to targeted models for pseudoxanthoma elasticum. J Invest Dermatol (2012) 1.08
ABCC6 as a target in pseudoxanthoma elasticum. Curr Drug Targets (2011) 1.04
Fibroblast involvement in soft connective tissue calcification. Front Genet (2013) 0.94
The vascular phenotype in Pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification. Front Genet (2013) 0.93
XT-II, the second isoform of human peptide-O-xylosyltransferase, displays enzymatic activity. J Biol Chem (2006) 0.92
Forward genetics defines Xylt1 as a key, conserved regulator of early chondrocyte maturation and skeletal length. Dev Biol (2013) 0.85
Xylosyltransferase II is a significant contributor of circulating xylosyltransferase levels and platelets constitute an important source of xylosyltransferase in serum. Glycobiology (2009) 0.81
New insights into the pathogenesis of pseudoxanthoma elasticum and related soft tissue calcification disorders by identifying genetic interactions and modifiers. Front Genet (2013) 0.78
First identification and functional analysis of the human xylosyltransferase II promoter. Glycoconj J (2012) 0.78
Mutation spectrum in the ABCC6 gene and genotype-phenotype correlations in a French cohort with pseudoxanthoma elasticum. Genet Med (2017) 0.75
Proteoglycans: structures and interactions. Annu Rev Biochem (1991) 6.53
Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet (2000) 3.07
Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat Genet (2000) 2.89
Mutations of the gene encoding the transmembrane transporter protein ABC-C6 cause pseudoxanthoma elasticum. J Mol Med (Berl) (2000) 2.04
Brief report: occult pseudoxanthoma elasticum in patients with premature cardiovascular disease. N Engl J Med (1993) 2.02
Pseudoxanthoma elasticum: mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc Natl Acad Sci U S A (2000) 1.97
Molecular cloning and expression of human UDP-d-Xylose:proteoglycan core protein beta-d-xylosyltransferase and its first isoform XT-II. J Mol Biol (2000) 1.49
Molecular genetics of pseudoxanthoma elasticum: type and frequency of mutations in ABCC6. Hum Mutat (2005) 1.47
Pseudoxanthoma elasticum: high calcium intake in early life correlates with severity. Am J Med Genet (1984) 1.26
Classification of pseudoxanthoma elasticum: report of a consensus conference. J Am Acad Dermatol (1994) 1.25
First isolation of human UDP-D-xylose: proteoglycan core protein beta-D-xylosyltransferase secreted from cultured JAR choriocarcinoma cells. J Biol Chem (2000) 1.14
Proteoglycan alterations in skin fibroblast cultures from patients affected with pseudoxanthoma elasticum. Cell Biochem Funct (1996) 1.03
Pseudoxanthoma elasticum. Int J Dermatol (1988) 0.95
Novel mutations in the ABCC6 gene of German patients with pseudoxanthoma elasticum. Hum Biol (2005) 0.92
Pseudoxanthoma elasticum. Biochemical and ultrastructural studies. Dermatologica (1981) 0.92
Determination of xylosyltransferase activity in serum with recombinant human bikunin as acceptor. Clin Chem (1997) 0.92
Assessment of a rapid-cycle PCR assay for the identification of the recurrent c.3421C>T mutation in the ABCC6 gene in pseudoxanthoma elasticum patients. Lab Invest (2004) 0.92
Elevated xylosyltransferase I activities in pseudoxanthoma elasticum (PXE) patients as a marker of stimulated proteoglycan biosynthesis. J Mol Med (Berl) (2005) 0.91
Serum xylosyltransferase: a new biochemical marker of the sclerotic process in systemic sclerosis. J Invest Dermatol (1999) 0.91
Mutational and functional analyses of xylosyltransferases and their implication in osteoarthritis. Osteoarthritis Cartilage (2005) 0.90
Molecular cloning of eukaryotic glycoprotein and glycolipid glycosyltransferases: a survey. Glycobiology (1995) 0.90
Anomalous structure of urinary glycosaminoglycans in patients with pseudoxanthoma elasticum. Clin Chem (2003) 0.90
Human xylosyltransferase I: functional and biochemical characterization of cysteine residues required for enzymic activity. Biochem J (2005) 0.88
New ABCC6 gene mutations in German pseudoxanthoma elasticum patients. J Mol Med (Berl) (2004) 0.88
Xylosylation of alternatively spliced isoforms of Alzheimer APP by xylosyltransferase. J Protein Chem (1998) 0.86
Impact of polymorphisms in the genes encoding xylosyltransferase I and a homologue in type 1 diabetic patients with and without nephropathy. Kidney Int (2005) 0.85
Effect of selective enzymatic digestions on skin biopsies from pseudoxanthoma elasticum: an ultrastructural study. Arch Dermatol Res (1986) 0.84
Elevated serum xylosyltransferase activity correlates with a high level of hyaluronate in patients with systemic sclerosis. Acta Derm Venereol (2000) 0.83
Biochemical analyses of macromolecular matrix components in patients with pseudoxanthoma elasticum. J Dermatol (1994) 0.83
Pseudoxanthoma elasticum (PXE): ultrastructural and biochemical study on proteoglycan and proteoglycan-associated material produced by skin fibroblasts in vitro. Coll Relat Res (1988) 0.83
Glycosaminoglycans of skin and urine in pseudoxanthoma elasticum: evidence for chondroitin 6-sulfate alteration. Clin Chim Acta (1986) 0.82
Haplotype variation and linkage disequilibrium in 313 human genes. Science (2001) 8.52
The sentinel node in breast cancer--a multicenter validation study. N Engl J Med (1998) 8.48
pHG165: a pBR322 copy number derivative of pUC8 for cloning and expression. Plasmid (1986) 3.15
Methadone in the management of intractable neuropathic noncancer pain. Can J Neurol Sci (2005) 2.23
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol (2006) 2.13
Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol (2001) 2.03
Glucose-regulated anaplerosis and cataplerosis in pancreatic beta-cells: possible implication of a pyruvate/citrate shuttle in insulin secretion. Diabetes (2000) 2.01
Mutant strains of Escherichia coli K12 that use D-amino acids. Proc Natl Acad Sci U S A (1971) 1.75
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J Virol (1998) 1.58
Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med (2004) 1.56
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res (2000) 1.55
High cell density cultivation of Escherichia coli at controlled specific growth rate. J Biotechnol (1991) 1.50
Molecular cloning and expression of human UDP-d-Xylose:proteoglycan core protein beta-d-xylosyltransferase and its first isoform XT-II. J Mol Biol (2000) 1.49
Wound therapy with autologous bone marrow stem cells in diabetic patients with ischaemia-induced tissue ulcers affecting the lower limbs. Int J Clin Pract (2007) 1.46
TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur J Immunol (1993) 1.44
Alterations in forearm vascular reactivity in patients with septic shock. Anaesthesia (2008) 1.43
Localization of regional lymph nodes in melanomas of the head and neck. Arch Otolaryngol Head Neck Surg (1998) 1.43
Use of bacterial luciferase to establish a promoter probe vehicle capable of nondestructive real-time analysis of gene expression in Bacillus spp. J Bacteriol (1987) 1.42
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia (2010) 1.42
Hepatitis C viremia in German blood donors: serum alanine aminotransferase is not a valid marker for screening. Transfusion (1994) 1.40
Bayesian analysis of pentaquark signals from CLAS data. Phys Rev Lett (2008) 1.39
The transcription of bacterial luminescence is regulated by sigma 32. J Biolumin Chemilumin (1989) 1.38
Measurement of two- and three-nucleon short-range correlation probabilities in nuclei. Phys Rev Lett (2006) 1.37
Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol (1993) 1.32
Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res (2010) 1.30
Synthesis and degradation of lac mRNA in E. coli depleted of 30S ribosomal subunits. Mol Gen Genet (1979) 1.27
Sequence and properties of operator mutations in the bio operon of Escherichia coli. Gene (1981) 1.23
Prepulse inhibition in psychiatric disorders--apart from schizophrenia. J Psychiatr Res (2013) 1.22
Role of D-tryptophan oxidase in D-tryptophan utilization by Escherichia coli. J Bacteriol (1976) 1.19
Differentiation of species of the Streptococcus bovis/equinus-complex by MALDI-TOF Mass Spectrometry in comparison to sodA sequence analyses. Syst Appl Microbiol (2011) 1.18
First isolation of human UDP-D-xylose: proteoglycan core protein beta-D-xylosyltransferase secreted from cultured JAR choriocarcinoma cells. J Biol Chem (2000) 1.14
Centrosomes and the Scrambled protein coordinate microtubule-independent actin reorganization. Nat Cell Biol (2001) 1.13
Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes. Mutagenesis (2001) 1.12
Protein-subunit aggregation model for self-incompatibility in higher fungi. Schizophyllum commune. J Theor Biol (1972) 1.10
Pseudorevertants of a lac promoter mutation reveal overlapping nascent promoters. Nucleic Acids Res (1989) 1.09
hOGG1 polymorphism and loss of heterozygosity (LOH): significance for lung cancer susceptibility in a caucasian population. Int J Cancer (2000) 1.09
Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J (1996) 1.06
Human xylosyltransferases in health and disease. Cell Mol Life Sci (2007) 1.05
Th1/Th2 cytokine gene expression after mercuric chloride in susceptible and resistant rat strains. Eur J Immunol (1996) 1.05
Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor. J Exp Med (2001) 1.02
Toscana virus causing severe meningoencephalitis in an elderly traveller. J Neurol Neurosurg Psychiatry (2005) 1.02
Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics (2001) 1.00
High cell density fermentation of recombinant Escherichia coli expressing human interferon alpha 1. Appl Microbiol Biotechnol (1990) 1.00
Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int J Cancer (2001) 0.99
Recognition of acceptor proteins by UDP-D-xylose proteoglycan core protein beta-D-xylosyltransferase. J Biol Chem (1997) 0.98
Surgical morbidity, mortality, and long-term survival in patients with peripancreatic cancer following pancreaticoduodenectomy. Am J Surg (1997) 0.98
An RNA helicase (AtSUV3) is present in Arabidopsis thaliana mitochondria. FEBS Lett (1999) 0.97
Encapsulation of bacteria and viruses in electrospun nanofibres. Nanotechnology (2006) 0.96
Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet (1984) 0.95
Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference. Cancer Gene Ther (2010) 0.95
The RNA world of plant mitochondria. Prog Nucleic Acid Res Mol Biol (2001) 0.95
Characterization of multidrug resistance by fluorescent dyes. Cancer Res (1991) 0.95
Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol (1995) 0.95
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. Clin Cancer Res (2000) 0.93
Determination of xylosyltransferase activity in serum with recombinant human bikunin as acceptor. Clin Chem (1997) 0.92
[Pseudoxanthoma elasticum]. Ophthalmologe (2006) 0.92
Serum xylosyltransferase: a new biochemical marker of the sclerotic process in systemic sclerosis. J Invest Dermatol (1999) 0.91
Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol (1996) 0.91
Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients. Int J Clin Pract (2012) 0.91
Mutational and functional analyses of xylosyltransferases and their implication in osteoarthritis. Osteoarthritis Cartilage (2005) 0.90
MR-compatibility assessment of the first preclinical PET-MRI insert equipped with digital silicon photomultipliers. Phys Med Biol (2015) 0.90
Structure and activity of insulin. XII. Further studies on biologically acitve synthetic fragments of the B-chain. Hoppe Seylers Z Physiol Chem (1973) 0.90
Nitroprusside-induced formation of cyanide and its detoxication with thiosulfate during deliberate hypotension. J Cardiovasc Pharmacol (1983) 0.89
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J Clin Oncol (2001) 0.89
Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics (2001) 0.89
Results of heart transplantation in patients with preexisting malignancies. Am J Cardiol (1997) 0.89
Granulocyte elastase as a new biochemical marker in the diagnosis of chronic joint diseases. Rheumatol Int (1986) 0.88
Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int Immunol (1993) 0.88
Fast generation of 4D PET-MR data from real dynamic MR acquisitions. Phys Med Biol (2011) 0.88
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol (2005) 0.88
Alpha 2-macroglobulin-proteinase complexes as correlated with alpha 1-proteinase inhibitor-elastase complexes in synovial fluids of rheumatoid arthritis patients. Arthritis Rheum (1986) 0.88
Identification of residues important both for primary receptor binding and specificity in fibroblast growth factor-7. J Biol Chem (2000) 0.87
Thalamic deep brain stimulation for Tourette syndrome. Behav Neurol (2013) 0.87
Necrotizing bronchitis, angiitis, and amyloidosis associated with chronic Q fever. Respiration (1995) 0.87
Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. Int Arch Occup Environ Health (2000) 0.87
Xylosylation of alternatively spliced isoforms of Alzheimer APP by xylosyltransferase. J Protein Chem (1998) 0.86
Fusion of LuxA and LuxB and its expression in E. coli, S. cerevisiae and D. melanogaster. J Biolumin Chemilumin (1990) 0.86
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res (1984) 0.86
Heparin-coated extracorporeal circulation with full and low dose heparinization: comparison of thrombin related coagulatory effects. Artif Organs (2001) 0.86
Encapsulation of bacterial cells in electrospun microtubes. Biomacromolecules (2009) 0.86
Fine-structural investigations of the effect of nCPAP-mask application on the nasal mucosa. Acta Otolaryngol (2000) 0.85
The clinical and radiographic features of massive neonatal adrenal hemorrhage. Radiology (1971) 0.85
Kinetics of elimination of thiocyanate in 7 healthy subjects and in 8 subjects with renal failure. Klin Wochenschr (1979) 0.85
Differential response of human naive and memory/effector T cells to dendritic cells infected by respiratory syncytial virus. Clin Exp Immunol (2007) 0.85
[Supplementary history and occupational dermatologic evaluation of medical bath workers, masseurs, and physical therapists]. Hautarzt (1998) 0.85
A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol (1991) 0.84